Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 401–500 of 1,000
Garrido, P., Pujol, J.-L., Kim, E. S., Lee, J. M., Tsuboi, M., Gómez‐Rueda, A., Benito, A., Moreno‐Mata, N., Gorospe, L., Dong, T., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1098 · Cited by 52
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 53
Rashid, R., Gaglia, G., Chen, Y.-A., Lin, J., Du, Z., Maliga, Z., Schapiro, D., Yapp, C., Muhlich, J. L., Sokolov, A., et al. (2019) · Scientific Data · doi:10.1038/s41597-019-0332-y · Cited by 54
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
Okada, M., Shimizu, K., & Fujii, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052594 · Cited by 52
“Despite the limited number of tumor-reactive T cells in patients, it is noteworthy that ICB treatment strongly increased tumor-specific T cells, including neoantigens, in humans and mice [10,76].”
BackgroundSové, R. J., Verma, B. K., Wang, H., Ho, W. J., Yarchoan, M. M., & Popel, A. S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005414 · Cited by 56
“61 66–68 72 For example, Ribba et al used reinforcement learning with a mechanistic model of tumor inhibition in glioma response to chemotherapy and radiotherapy in application to precision dosing 69 Despite the lack of clinical data availability, QSP model simulations produce a large amount of…”
Self-citationLiu, D.-X., Li, D., He, W., Ke, C., Wu, J., Tang, J.-H., Kong, L.-H., Li, Y., Sui, Q., Xiao, B.-Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1711650 · Cited by 50
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
Grant, C., & Nagasaka, M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102724 · Cited by 60
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy
Darragh, L. B., & Karam, S. D. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00903-x · Cited by 60
Wang, X., Kong, C., Xu, W., Yang, S., Shi, D., Zhang, J., Du, M., Wang, S., Bai, Y., Zhang, T., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13163 · Cited by 51
Self-citationThe neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC
Stafford, M. A., & Kaczmar, J. M. (2020) · Cancers of the Head & Neck · doi:10.1186/s41199-020-00052-8 · Cited by 48
Workenhe, S. T., Nguyen, A., Bakhshinyan, D., Wei, J., Hare, D. N., MacNeill, K. L., Wan, Y., Oberst, A., Bramson, J. L., Nasir, J. A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01362-w · Cited by 56
Pan, L., Ma, Y., Li, Z., Hu, J., & Xu, Z. (2020) · Cell Biology International · doi:10.1002/cbin.11524 · Cited by 58
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Jiang, L., Huang, J., Jiang, S., Rong, W., Shen, Y., Li, C., Tian, Y., Ning, J., Chen, X., Yang, Y., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02847-1 · Cited by 49
“According to previous studies, secondary analyses of former small pilot prospective studies, the approach of lung resection after neoadjuvant therapy is safe and reliable [10, 11, 32].”
van de Donk, P. P., Wind, T. T., Hooiveld-Noeken, J. S., van der Veen, E. L., Glaudemans, A. W. J. M., Diepstra, A., Jalving, M., de Vries, E. G. E., de Vries, E. F. J., & Hospers, G. A. P. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05407-y · Cited by 52
Imaging CAR T-cell kinetics in solid tumors: Translational implications
Skovgard, M. S., Hocine, H. R., Saini, J. K., Moroz, M. A., Bellis, R. Y., Banerjee, S., Morello, A., Ponomarev, V., Villena‐Vargas, J., & Adusumilli, P. S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.006 · Cited by 54
“Similarly, some patients treated with induction immunotherapy experience tumor enlargement after therapy or the absence of visible regression on imaging; however, they demonstrate tumor cell death of up to 90% and extensive immune cell infiltration on pathological assessment.(12) A noninvasive imaging modality that ca…”
Chen, J., Li, S., Yao, Q., Du, N., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01933-5 · Cited by 48
Du, Y., Peng, Q., Cheng, D., Pan, T. S., Sun, W., Wang, H., Ma, X., He, R.-R., Zhang, H., Cui, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27936-8 · Cited by 56
Self-citationDervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 56
Neoadjuvant therapy in non-small cell lung cancer
Grant, C., Hagopian, G. G., & Nagasaka, M. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104080 · Cited by 55
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Awada, G., Cascone, T., van der Heijden, M. S., Blank, C. U., Kok, M., & Chalabi, M. (2025) · Nature Cancer · doi:10.1038/s43018-025-00990-7 · Cited by 54
“The first pilot study that evaluated the feasibility and safety of neoadjuvant nivolumab mono-therapy in stage I–IIIA resectable NSCLC showed an MPR rate of 45% 45,67 .”
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 51
Use of Circulating Tumor DNA for Cancer Immunotherapy
Snyder, A., Morrissey, M., & Hellmann, M. D. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2688 · Cited by 48
“In a study of neoadjuvant PD-1 blockade, the rate of radiologic response was only 10% compared with the rate of major pathologic response of 45% in the same patients (59).”
ResultSelf-citationBrunelli, A., Rocco, G., Szántó, Z., Thomas, P. A., & Falcoz, P. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz287 · Cited by 57
“The promising preliminary findings of immunotherapy and chemotherapy delivered in the neoadjuvant setting [3, 4] and the probable increased utilization of this approach in the near future warrant a timely analysis of postoperative outcome associated with induction therapy.”
BackgroundThe methods and advances of adaptive immune receptors repertoire sequencing
Liu, H., Pan, W., Tang, C., Tang, Y., Wu, H., Yoshimura, A., Deng, Y., He, N., & Li, S. (2021) · Theranostics · doi:10.7150/thno.61390 · Cited by 51
“After 2-4 weeks of treatment, an increase in antigen-specific T cell clones was observed, and these clones were not detected without nivolumab treatment, further proving that PD-1 blockade promoted intratumoral T cell killing and enhanced tumor antigen-driven priming of T cells [145].”
BackgroundYang, H., Sun, B., Ma, W., Fan, L., Xu, K., Jia, Y., Xu, J., Wang, Z., & Yao, F. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104265 · Cited by 52
Lee, H., Jang, H.-J., Ramineni, M., Wang, D. Y., Ramos, D., Choi, J. M., Splawn, T. G., Espinoza, M., Almarez, M., Hosey, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2566 · Cited by 53
Liu, S., Dong, S., Yang, X., Liao, R.-Q., Jiang, B., Wang, Q., Ben, X., Qiao, G., Lin, J., Yan, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01700-4 · Cited by 57
“12,14,23,24 Therefore, the ability of PD-L1 expression in identifying patients that would potentially bene fi t most from immunochemotherapy or monotherapy remains unclear.”
BackgroundLong, G. V., Carlino, M. S., Au‐Yeung, G., Spillane, A. J., Shannon, K. F., Gyorki, D. E., Hsiao, E., Kapoor, R., Thompson, J., Batula, I., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03077-5 · Cited by 49
“Importantly, previous neoadjuvant trials have reported that pathological response outcomes are often better than anticipated by presurgical RECIST response 22,25,36,37 .”
Xu, Z., Li, H., Dong, Y., Cheng, P., Luo, F., Fu, S., Gao, M., Kong, L., & Che, N. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s241231 · Cited by 46
Li, N., Yuan, J., Tian, W., Meng, L., & Liu, Y. (2020) · 癌症:英文版 · doi:10.1002/cac2.12074 · Cited by 54
“early-stage (I, II, or IIIA) non-small-cell lung cancer (NSCLC) [1].”
BackgroundMethodInfluentialKang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 48
Lymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 47
Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44195-x · Cited by 52
“In the neoadjuvant space, blockade of the PD-1/PD-L1 immune checkpoint combined with preoperative chemotherapy is also a new standard of care for patients with stages IB-IIIA NSCLC regardless of PD-L1 expression 6 – 8 .”
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 67
de Miguel‐Pérez, D., Bayarri-Lara, C. I., Ortega, F. G., Russo, A., Rodríguez, M. J. M., Álvarez-Cubero, M. J., Serrano, E. M., Lorente, J. A., Rolfo, C. D., & Serrano, M. J. (2019) · Cancers · doi:10.3390/cancers11111750 · Cited by 46
“Recently, immunotherapy has emerged as an effective treatment strategy in advanced/metastatic NSCLC and is rapidly moving in the neo/adjuvant setting with promising results [41].”
BackgroundLoeffler, M. W., Nussbaum, B., Jäger, G., Jurmeister, P. S., Budczies, J., Pereira, P. L., Clasen, S., Kowalewski, D. J., Mühlenbruch, L., Königsrainer, I., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02526 · Cited by 49
Borcoman, É., Dupont, A., Mariotte, É., Doucet, L. S., Joseph, A., Chermak, A., Valade, S., Resche‐Rigon, M., Azoulay, É., & Lemiale, V. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.01.027 · Cited by 49
Current status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
“Some studies have indicated that a higher neoantigen burden and TMB are close correlated with increased efficacy of immunotherapies in diverse cancer types, including bladder cancer (Legrand et al., 2018), small cell lung cancer (Hellmann et al., 2019), independent cohorts of non-small-cell lung cancer (NSCLC) (Forde…”
BackgroundNeoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
Tfayli, A., Assaad, M. A., Fakhri, G. B., Akel, R., Atwi, H., Ghanem, H., Karak, F. E., Farhat, F. S., rabi, K. A., Sfeir, P. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3456 · Cited by 45
Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Lee, J. M., Tsuboi, M., & Brunelli, A. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.06.069 · Cited by 49
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
Xiong, W. G., Zhao, Y., Du, H., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704336 · Cited by 51
“Initial efficacy of neoadjuvant immunotherapy in resectable disease was quite promising based on 45% of major pathological response (MPR), which was defined as <10% viable tumor in the resected surgical specimen (42, 43).”
BackgroundZhang, X., Gari, A., Li, M., Chen, J., Qu, C., Zhang, L., & Chen, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03252-7 · Cited by 49
“This is consistent with other studies reporting that nivolumab monotherapy showed a pCR of 43% in patients with resectable non-small-cell lung cancer [13], though the rate was 20% in lung cancer patients with metastatic disease when nivolumab was considered as an adjuvant [14].”
ResultLu, C., Gao, Z., Wu, D., Zheng, J., Hu, C., Huang, D., He, C., Liu, Y., Lin, C., Peng, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009165 · Cited by 53
“4 Unlike the response to TKIs, the overall response rate to ICIs may be lower, 5 6 but for patients who”
Pradhan, M., Chocry, M., Gibbons, D. L., Sepesi, B., & Cascone, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-573 · Cited by 48
“In the first feasibility study of 21 patients with operable NSCLC treated with neoadjuvant nivolumab, there was no association between MPR and expression of PD-L1 in pretreatment tumor biopsies (16).”
BackgroundMethodResultInfluentialWedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 50
Dai, M., Liu, M., Yang, H., Küçük, C., & You, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00356-0 · Cited by 53
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 45
Zhou, B., Bie, F., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhao, J., & Gao, S. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104268 · Cited by 45
Lin, Q., Wu, H. J., Song, Q. S., & Tang, Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.937277 · Cited by 46
“In previous clinical studies, either single-agent ICI or immune doublet combination NAT significantly led to higher MPR and CPR rates and lower complication rates than neoadjuvant chemotherapy (11, 12).”
Rusch, V. W., Nicholas, A., Patterson, G. A., Waqar, S. N., Toloza, E. M., Haura, E. B., Raz, D. J., Reckamp, K. L., Merritt, R. E., Owen, D. H., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.10.007 · Cited by 47
“29,31 Therefore, more detailed studies in larger clinical trials were needed to further confirm the safety and efficacy of IO followed by potentially curative surgery.”
BackgroundSelf-citationCryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy
Velez, A., DeMaio, A. J., & Sterman, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203539 · Cited by 43
“resection (63), and the addition of cryoablation to such a regimen at the time of bronchoscopy could theoretically further enhance this effect, particularly in those lung cancers with “cold” baseline immune microenvironments (low PD-L1 expression and absence of infiltrating T cells).”
BackgroundBrandt, W. S., Yan, W., Zhou, J. H., Tan, K. S., Montecalvo, J., Park, B. J., Adusumilli, P. S., Huang, J. G., Bott, M. J., Rusch, V. W., et al. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.09.098 · Cited by 46
Self-citationResearch progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 51
The tumour immune microenvironment in oesophageal cancer
Davern, M., Donlon, N. E., Power, R. F., Hayes, C., King, R., Dunne, M. R., & Reynolds, J. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01331-y · Cited by 50
“Using the TMB and an immune scoring system to predict the therapeutic outcome is an attractive approach, as strongly evident from the results of studies of NSCLC, in which the pre-treatment TMB positively correlated with the pathological response.(122) A genomic analysis of the TME of 1,524 patients with GC identified…”
ResultResponse to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota
He, D., Li, X., An, R., Wang, L., Wang, Y., Zheng, S., Chen, X., & Wang, X. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00171-3 · Cited by 46
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1382 · Cited by 47
Vos, J. L., Zuur, C. L., Smit, L. A., de Boer, J. P., Al‐Mamgani, A., van den Brekel, M. W. M., Haanen, J. B. A. G., & Vogel, W. V. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05610-x · Cited by 46
“Consequently, objective response rates assessed per RECIST have been shown to underestimate both the depth and incidence of pathological responses to neoadjuvant ICB in melanoma, colon cancer, non-small cell lung cancer, and HNSCC [3, 4, 6, 7, 10].”
BackgroundMethodA variety of ‘exhausted’ T cells in the tumor microenvironment
Nagasaki, J., & Togashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac013 · Cited by 45
Chen, Y., Qin, J., Wu, Y., Lin, Q., Wang, J., Zhang, W., Liang, F., Hui, Z., Zhao, M., & Wang, J. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000496 · Cited by 49
“The CheckMate 159 research showed that neoadjuvant nivolumab achieved MPR in 45% of participants [37] .”
InfluentialDeterminants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
“Moreover, blockade before surgery in the clinical setting has contributed to the expansion of neoantigen-specific T-cell clones in NSCLC patients [153].”
BackgroundParacrine and cell autonomous signalling in pancreatic cancer progression and metastasis
Thomas, S. K., Lee, J., & Beatty, G. L. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102662 · Cited by 47
“For PDAC that is surgically-resectable, this might mean incorporating a short course of neoadjuvant immunotherapy prior to surgical resection, as has been done recently in lung cancer and melanoma [85,86], with the goal to contain the metastatic ability of residual cancer cells in the post-operative setting.”
BackgroundIL-17A and IL-17F orchestrate macrophages to promote lung cancer
Ferreira, N. L. C., Mesquita, I., Baltazar, F., Silvestre, R., & Granja, S. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00510-y · Cited by 47
Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
Yang, M., Oh, I. Y., Mahanty, A., Jin, W., & Yoo, J. S. (2020) · Cancers · doi:10.3390/cancers12092334 · Cited by 46
“In particular, immunostimulatory therapy following surgery resection might be more beneficial to reduce residual disease burden and thus improve the likelihood of clinical benefits [106].”
BackgroundEffect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen, C., Liu, Y., & Cui, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1840254 · Cited by 45
“treatment, there are also some patients with negative PD-L1 who can benefit from it.(106,107) Therefore, the efficacy of ICBs”
BackgroundThe Current Lung Cancer Neoantigen Landscape and Implications for Therapy
Ye, L., Creaney, J., Redwood, A., & Robinson, B. W. S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1624 · Cited by 44
Immunotherapy use outside clinical trial populations: never say never?
Rzeniewicz, K., Larkin, J., Menzies, A. M., & Turajlic, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.199 · Cited by 43
Molecular imaging to support cancer immunotherapy
van de Donk, P. P., Oosting, S. F., Knapen, D. G., van der Wekken, A. J., Brouwers, A. H., Hooge, M. N. L., de Groot, D. J., & de Vries, E. G. E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004949 · Cited by 44
Tang, X., Li, M., Wu, X., Guo, T., Zhang, L., Tang, L., Jia, F., Hu, Y., Zhang, Y., Xing, X., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2135819 · Cited by 46
Zhai, W.-Y., Zhao, Z.-R., Chen, S., Yu, H., Lin, Y., Wang, Y., & Long, H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005160 · Cited by 45
Bioinformatics analysis of the circRNA–miRNA–mRNA network for non-small cell lung cancer
Cai, X., Lin, L., Zhang, Q., Wu, W., & Su, A. (2020) · Journal of International Medical Research · doi:10.1177/0300060520929167 · Cited by 41
“Radiotherapy, chemotherapy, and biotargeted therapy can be used in combination in advanced patients while avoiding unnecessary surgery.(9) However, the prognosis of patients is far from satisfactory because of the high tumor recurrence and metastasis rates.”
BackgroundSzeto, C. H., Shalata, W., Yakobson, A., & Agbarya, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235614 · Cited by 45
“The LCMC3 study recruited 181 patients with untreated resectable stage IB–IIIB NSCLC from 21 centers in the United States [17].”
BackgroundMethodInfluentialJiang, C., Li, X., Wan, S., Ji, S., Wang, Q., Hu, S., Chen, P., Wang, B., Tao, G., Zhang, J., et al. (2025) · Small · doi:10.1002/smll.202503208 · Cited by 47
Self-citationNew windows open for immunotherapy in lung cancer
Hendriks, L. E. L., & Besse, B. (2018) · Nature · doi:10.1038/d41586-018-05312-9 · Cited by 46
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
Carmichael, J. A., Mak, D. W.-S., & O'Brien, M. E. R. (2018) · Cancers · doi:10.3390/cancers10070236 · Cited by 45
“Furthermore, recent data also suggests a role in stage III following chemoradiotherapy [108], and in the neo-adjuvant setting [111].”
BackgroundThe Future of Perioperative Therapy in Advanced Renal Cell Carcinoma: How Can We Prosper?
Patel, H. D., Puligandla, M., Shuch, B. M., Leibovich, B. C., Kapoor, A., Master, V. A., Drake, C. G., Heng, D. Y., Lara, P. N., Choueiri, T. K., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0951 · Cited by 44
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
“This corroborates the documentation of new neoantigen-specific T cell responses in the TME of matched pre and posttreatment biopsies of melanoma tumors following 2 doses of neoadjuvant nivolumab [130].”
ResultJohn, A. O., & Ramnath, N. (2023) · The Oncologist · doi:10.1093/oncolo/oyad125 · Cited by 46
Gong, J., Hendifar, A. E., Tuli, R., Chuang, J., Cho, M. T., Chung, V. M., Li, D., & Salgia, R. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0210-9 · Cited by 42
Mauclet, C., Duplaquet, F., Pirard, L., Rondelet, B., Dupont, M., Pop, C. S., Borght, T. V., Remmelink, M., D’Haene, N., Lambin, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.006 · Cited by 40
Novel treatment strategies for early-stage lung cancer: the oncologist’s perspective
Indini, A., Rijavec, E., Bareggi, C., & Grossi, F. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.02.46 · Cited by 44
“A pilot study of neoadjuvant nivolumab showed that 45% of patients with surgically resectable stage I–IIIA NSCLC reach major pathological response with only 2 courses of preoperative nivolumab, with few treatment-related side effects and without surgery delay (37).”
BackgroundImportant Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
Lee, J. M., Kim, A. W., Marjański, T., Falcoz, P., Tsuboi, M., Wu, Y.-L., Sun, S. W., & Gitlitz, B. J. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100221 · Cited by 49
“…atezolizumab and within <15 d of that window 30 (100%)/30 Median, 24 d None delayed >15 d 0% 0% 0% NCT02259621 CheckMate 159 Bott et al. (2019)41 Forde et al. (2018)14 I–IIIA Nivolumab (3 cycles on d 42, 28, 14 [±2 d] before surgery on d 0) Approximately 4 wk after the first neoadjuvant…”
BackgroundXia, L., Guo, L., Kang, J. U., Yang, Y., Yao, Y., Xia, W., Sun, R., Zhang, S., Li, W., Gao, Y.-E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759217 · Cited by 43
“For instance, PD-1 blockade induces Ki67 expression in a subset of peripheral PD-1CD8 T cells and the expansion of neoantigen-specific T cell clones after anti-PD1 treatment, which suggests the restoration of systematic antitumor immunity of CD8 T cells after receiving ICI immunotherapy (8, 9).”
BackgroundGovindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 50
Self-citationNeoadjuvant immunotherapy of locoregionally advanced solid tumors
Tarhini, A. A., Eads, J. R., Moore, K. N., Tatard-Leitman, V. M., Wright, J., Forde, P. M., & Ferris, R. L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005036 · Cited by 41
Self-citationWu, J., Hou, L., Haoran, E., Zhao, Y., Yu, X., Xu, L., Ye, N., Deng, J., Sun, K., Zhang, J., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.019 · Cited by 45
Self-citationZhang, C., Chen, H., Shi, Y., Wu, L., Yan, L., Yan, X., Yue, D., Xu, C., Zheng, M., Li, J., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00301-8 · Cited by 45
Li, S., Xu, Q., Dai, X., Zhang, X., Huang, M., Huang, K., Shi, D., Wang, J., & Liu, L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13143-w · Cited by 40
“Generally, gastric cancer is not a hot tumor that benefits from ICI as much as NSCLC, in which neoadjuvant ICIbased therapy has achieved huge success.(13,23) In NSCLC, nivolumab alone can elicit 15–30% pCR and 45–50% MPR, much superior to chemotherapy.”
BackgroundBiomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
Tostes, K., Siqueira, A. P., Reis, R. M., Leal, L. F., & Arantes, L. M. R. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511887 · Cited by 46
“Additionally, tumor-infiltrating immune cells in the tumor environment demonstrate increased levels of PD-L1 expression, and the administration of ICI leads to an enhanced influx of CD8+ T lymphocytes in the tumor region [58].”
BackgroundDickhoff, C., Senan, S., Schneiders, F. L., Veltman, J. D., Hashemi, S. M. S., Daniels, J. M. A., Fransen, M. F., Heineman, D. J., Radonic, T., van de Ven, P. M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07263-9 · Cited by 42
Biewenga, M., van der Kooij, M. K., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Boers‐Sonderen, M. J., Hospers, G. A. P., Piersma, D., van Rijn, R. S., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10151-4 · Cited by 45
Neoadjuvant PD-1 Inhibitors and Chemotherapy for Locally Advanced NSCLC: A Retrospective Study
Chen, T., Ning, J., Campisi, A., Dell’Amore, A., Ciarrocchi, A. P., Li, Z., Song, L., Huang, J., Yang, Y., Stella, F., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.03.041 · Cited by 40
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Etxeberría, I., Bolaños, E., Teijeira, Á., Garasa, S., Yanguas, A., Azpilikueta, A., Kavanaugh, W. M., Vasiljeva, O. S., Belvin, M. P., Howng, B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025930118 · Cited by 42
Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
Kaur, J., Elms, J., Munn, A. L., Good, D. M., & Wei, M. Q. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103417 · Cited by 44
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
Fransen, M. F., van Hall, T., & OSSENDORP, F. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179401 · Cited by 45
“In a trial with NSCLC patients, however, a far greater level of adverse events was found than seen in end-stage patients treated with the same regimen, possibly due to the patient’s lower disease burden and greater overall fitness at the time of the start of immunotherapy [56].”
BackgroundWanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 43
The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
Aghbash, P. S., Hemmat, N., Baradaran, B., Mokhtarzadeh, A., Poortahmasebi, V., Oskouee, M. A., & Baghi, H. B. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026776 · Cited by 41
Yang, G., Cai, S., Hu, M., Li, C., Yang, L., Zhang, W., Sun, J., Sun, F., Xing, L., & Sun, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04154-y · Cited by 44
“Given that the primary tumor may be an antigen source for activating and expanding tumor-specific T cells and systemic surveillance of micrometastases, neoadjuvant immunotherapy is promising [46].”
BackgroundTumor-Infiltrating Lymphocytes—Location for Prognostic Evaluation
Peled, M., Onn, A., & Herbst, R. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3803 · Cited by 38
“Interestingly, immunotherapy was recently tested also as a neoadjuvant treatment for early-stage NSCLC (7), to induce an immunologic memory that will potentially reduce recurrence rate.”
BackgroundToward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Mylvaganam, G., Yanez, A. G., Maus, M. V., & Walker, B. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02109 · Cited by 38
Miyawaki, T., Kenmotsu, H., Mori, K. P., Miyawaki, E., Mamesaya, N., Kawamura, T., Kobayashi, H., Omori, S., Wakuda, K., Ono, A., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.012 · Cited by 39
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.